RGEN - Danaher Q1: The Worst Time Has Already Passed

2024-04-25 17:01:08 ET

Summary

• Danaher Corporation stock has surged by 16% since our "Strong Buy" rating in June 2023, outperforming the S&P 500.
• The bioprocessing industry is facing near-term challenges, but long-term growth prospects remain strong.
• Danaher's Q1 FY24 results showed a 4% organic revenue decline, but the company's strong leadership and role in the biotech industry inspire confidence.

Since I presented my "Strong Buy" view on Danaher Corporation ( DHR ) in June 2023, the stock price has surged by 16%, outpacing the S&P 500 (SP500) performance. At that time, I highlighted the near-term challenges of the bioprocessing industry and expressed my long-term optimism about their growth prospects....

For further details see: